Brief Report

Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort

Javier Vázquez-Bourgon, Jaqueline Mayoral-van Son, Marcos Gómez-Revuelta, María Juncal-Ruiz, Víctor Ortiz-García de la Foz, Diana Tordesillas-Gutiérrez, Rosa Ayesa-Arriola, Miquel Bioque, Benedicto Crespo-Facorro

Department of Psychiatry, University Hospital Marqués de Valdecilla - Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (Dr Vázquez-Bourgon, Dr Gómez-Revuelta, Mr Ortiz-García de la Foz, Dr Tordesillas-Gutiérrez, and Dr Ayesa-Arriola); Department of Psychiatry, Hospital Sierraclana - Instituto de Investigacion Marques de Valdecilla (IDIVAL), Torrelavega, Spain (Dr Juncal-Ruiz); Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Madrid, Spain (Drs Vázquez-Bourgon, Mayoral-van Son, Tordesillas-Gutiérrez, Ayesa-Arriola, Bioque, and Crespo-Facorro); Department of Medicine and Psychiatry, School of Medicine, University of Cantabria, Santander, Spain (Drs Vázquez-Bourgon, Gómez-Revuelta, Juncal-Ruiz, Tordesillas-Gutiérrez, Ayesa-Arriola); Department of Psychiatry, School of Medicine, University Hospital Virgen del Rocio-IBIS, Sevilla, Spain (Drs Mayoral-van Son and Crespo-Facorro); Barcelona Clinic Schizophrenia Unit, Hospital Clinic de Barcelona, Universitat de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (Dr Bioque). J.V.-B. and J.M.-v.S. contributed equally to the manuscript.

Correspondence: Javier Vázquez-Bourgon, MD, PhD, Department of Psychiatry, University Hospital Marques de Valdecilla. Avda.Valdecilla s/n, Santander 39008, Spain (javier.vazquez@scsalud.es).

Abstract

Background: Patients with a first episode of psychosis (FEP) are at higher risk of gaining weight and presenting metabolic disturbances, partly related to antipsychotic exposure. Previous studies suggest that treatment discontinuation might have a positive impact on weight in schizophrenia. The aim of this study was to evaluate the effect of treatment discontinuation on weight and metabolic changes in a FEP cohort.

Methods: A total of 209 FEP patients and 57 healthy controls were evaluated at study entry and prospectively at 10-year follow-up. Anthropometric measures and, clinical, metabolic, and sociodemographic data were collected.

Results: Patients discontinuing antipsychotic treatment presented a significantly lower increase in weight and better metabolic parameter results than those still on antipsychotic treatment at 10-year follow-up.

Conclusions: Treatment discontinuation had a positive effect on the weight and metabolic changes observed in FEP patients; however, this effect was not sufficient to reaching a complete reversal to normal levels.

Key Words: Treatment discontinuation, lipid metabolism, weight gain, medication-naïve, second-generation antipsychotic
Introduction

Patients with schizophrenia spectrum disorders are at higher risk of presenting increments in body weight and related metabolic disturbances, such as dyslipidemia and glucose intolerance, which mediate in the decrease of life expectancy observed in psychosis (Melle et al., 2017). These abnormalities have been observed early in the course of the psychotic disorder (Perez-Iglesias et al., 2007) but usually keep progressing at long-term observed early in the course of the psychotic disorder (Perez-Iglesias et al., 2007). These abnormalities have been observed in the patients, suggesting that the consolidated metabolic dysregulation associated with the antipsychotic treatment is maintained long term (Mackin et al., 2012). Similarly, Wu and colleagues (Wu et al., 2014) reported that compared with antipsychotic-treated schizophrenia patients, antipsychotic-discontinuation patients showed a smaller BMI, although the differences did not reach statistical significance.

In addition to the scarcity of data in this topic, there are no previous studies, to our knowledge, on FEP patients following a longitudinal prospective approach that analyze the impact of treatment discontinuation on weight and metabolic changes long term (10 years).

This study aimed to explore prospectively the effect of treatment discontinuation on the pattern of weight changes and the occurrence of metabolic disturbances in a FEP cohort followed for the first 10 years of their psychosis. Taking into account the above evidences, we hypothesized that those patients discontinuing antipsychotic treatment would present significantly lower increments in weight and metabolic disturbances than those patients continuing on antipsychotic treatment after 10 years of the FEP.

Methods

Study Setting

The present study was part of a larger prospective longitudinal study on first-episode, non-affective psychosis: the “First Episode Psychosis Clinical Program 10” (PAFIP-10) study (Ayesa-Ariola et al., 2019).

The study was approved by the local ethics committee for clinical research (CEIC-Cantabria) in accordance with international standards for research ethics. Patients included in the study provided written informed consent for entry initially into PAFIP and for PAFIP-10 reassessment.

Baseline Inclusion Criteria

All referrals to PAFIP between February 2001 and July 2008 were screened against the following inclusion criteria: age 15–60 years; living in the catchment area; experiencing their FEP; no prior treatment with antipsychotic medication or, if previously treated, a total life-time of adequate antipsychotic treatment of less than 6 weeks. DSM-IV criteria for drug or alcohol dependence, intellectual disability, and a history of neurological disease or head injury were exclusion criteria. The diagnoses were confirmed through the use of the Structured Clinical Interview for DSM-IV (First et al., 1996) conducted by an experienced psychiatrist at 6 months from the baseline visit.

Patient Clinical Assessment and Psychopharmacological Treatment

Baseline sociodemographic and clinical information were recorded from interviews with patients or their relatives and from medical records on admission. Clinical data for this study were collected by the same senior consultant psychiatrist (B.C.-F.) at baseline and at the 10-year follow-up.

All patients were, at baseline, randomly assigned to oral antipsychotic medication. Antipsychotic doses could be adjusted as clinically indicated within the prescribed range in an attempt to target the lowest effective dose.

Patients were clustered in 2 groups (“treatment continuation” vs “treatment discontinuation”) based on patients’ self-reports and medical records; patients were included in the “discontinuation group” if they reported not taking antipsychotic treatment at the 10-year reassessment.

Healthy individuals (n = 57) without psychiatric illness were recruited as control group and evaluated at baseline and 10 years after. Sociodemographic, clinical, and anthropometric measures were collected. Lipid and glycemic examinations, through laboratory analyses, were also performed at both time-points.

Laboratory Analyses

All determinations were performed at the same site, in our hospital, including both biochemical and endocrinology analysis. All measurements were obtained, after an overnight fast, at baseline and 10-year follow-up. Fasting state as well as treatment compliance were reported by patients and their family members. A full description of the technical methods related to
the laboratory analyses is reported elsewhere (Vázquez-Bourgon et al., unpublished observations).

Statistical Analyses
Statistical analyses were carried out to explore the impact of antipsychotic medication discontinuation on long-term weight and metabolic changes. For this, we compared those patients taking antipsychotic medication at 10-year follow-up (n = 175) with those who had previously discontinued it (n = 34) and with the control group (n = 57). For this purpose, ANCOVA analyses were carried out, where parameter change was used as the dependent variable, participant group (patients on antipsychotic treatment vs discontinuers) was the fixed factor, and baseline BMI, baseline parameter data, age, and sex were used as covariates.

In addition, we calculated the differences in the percentage of patients meeting the criteria for obesity and metabolic disorders from baseline to the 10-year follow-up. To evaluate significant changes in these percentages, we used the McNemar test for repeated measures.

The Statistical Package for Social Science (SPSS) version 22.0 (IBM, Armonk, NY) was used for the statistical analyses. All statistical tests were 2-tailed, and the significance was determined at the .05 level.

RESULTS
Cohort Characteristics
Between February 2001 and July 2008, 307 patients took part in the PAFIP study and were assessed at baseline. Of these, 10 patients died during the follow-up period (including 4 deaths from suicide). Of the 297 remaining participants, 209 (70.4%) completed the 10-year follow-up reassessment (PAFIP-10). Briefly, at program admission, the patients had a mean age of 28.1 years (SD = 8.3), 54.5% were male, and most of them were White Caucasian (98.6%).

Of the 209 patients in the present study, 30 (14.4%) were initially treated with aripiprazole (a D2 and 5-HT1A receptor partial agonist, and 5-HT2A receptor antagonist), 40 (19.1%) with risperidone (a D2, 5-HT2, and NE alpha-2 receptor antagonist), 28 (13.4%) with quetiapine (a D2 and 5-HT2 receptor antagonist, and NET -metabolite- reuptake inhibitor), 32 (15.3%) with ziprasidone (a D2 and 5-HT2 receptor antagonist), 40 (19.1%) with olanzapine (a D2 and 5-HT2 receptor antagonist), and 39 (18.7%) with haloperidol (a D2 receptor antagonist).

At the 10-year follow-up assessment, 34 patients (16.3%) had previously discontinued the antipsychotic treatment. The mean time to discontinuation was 4.5 years, and the mean time from discontinuation to 10-year follow-up (period without antipsychotic exposure) was 7.4 years (SD = 3.3). Among those still on antipsychotic treatment, 39 (18.7%) continued with the same antipsychotic medications throughout the 10-year follow-up.

Statistical Analyses
for the Assessment of Positive Symptoms (SAPS) score at baseline than those patients who discontinued antipsychotic treatment throughout the 10-year follow-up.

Treatment Discontinuation Effect on Weight and Metabolic Differences After 10 Years From Psychosis Breakout
The ANCOVA analyses comparing the 3 groups (treated patients, discontinued patients, control group) showed significant differences in the long-term changes in weight, BMI, and waist circumference between the 3 groups (all P < .001). Results from post-hoc comparisons remained significantly different between the patient groups (treated vs discontinued) and between the treated patients and the control group, but not between the discontinued and the control groups. Weight and waist circumference changes over the 10-year study were progressive between groups, from the control group (the smallest changes), to the discontinuation group, and finally the treated patients group (the greatest changes) (Table 1).

Data from direct comparison (ANCOVA) between the 2 patient groups, excluding the control group from the analyses (supplementary Table 2), showed that apart from the significant differences in weight and BMI changes described above, those patients who discontinued their antipsychotic treatment presented a better progression in metabolic parameters than those still on antipsychotic treatment, with statistical analyses reaching statistical significance for mean changes in high-density lipoprotein (1.44 vs −2.10 mg/dL, F = 4.12, P = .044) and triglycerides-high-density lipoprotein index (0.33 vs 1.27, F = 4.42, P = .037) and trend toward association for mean changes in triglycerides (22.04 vs 48.65 mg/dL, F = 3.04, P = .076), homeostasis model assessment index (0.80 vs 1.13, F = 3.04, P = .084), and insulin (3.23 vs 3.71, F = 3.87, P = .051).

These differences in weight and metabolic changes between patient groups are reflected in the clinical impact; thus, the increment in the percentage of patients meeting criteria for obesity and other metabolic disorders after the 10-year follow-up is remarkably less pronounced in the treatment discontinuation group than in the continuation group (Table 2).

Discussion
This study replicated our previous results (Vázquez-Bourgon et al., unpublished observations) showing a relation between antipsychotic medication exposure and weight gain at long term (10 years) in psychosis. However, it also shows that discontinuing antipsychotic treatment was associated with a smaller increase in weight and waist circumference at long term (10 years) in a sample of patients followed-up after their FEP. Research studies focusing on the effect of antipsychotic discontinuation on weight and metabolic alteration reversibility are scarce. However, these results are in line with indirect data from a previous study comparing adherent and non-adherent schizophrenia patients (Lindenmayer et al., 2009) and showing that non-adherent patients presented significantly lower increments in body weight than adherent patients (1.96 kg vs 2.63 kg, P = .02). Similarly, discontinuation of antipsychotic treatment in a small group of hospitalized children and adolescents (Hulvershorn et al., 2017) was associated with reductions in BMI. And Wu and colleagues (Wu et al., 2014) observed that antipsychotic discontinuation patients presented a smaller BMI (23.09 vs 22.28) than the antipsychotic-treated schizophrenia patients, although the differences did not reach statistical significance. In this case, the
This evidence suggests that antipsychotic exposure does not explain on its own the weight gain and metabolic disturbances observed in FEP patients. The gradual weight gain differences between non-psychiatric healthy controls, “antipsychotic-discontinuation” patients, and “antipsychotic-treated” patients (3.4, 8.2, and 16.5 kg, respectively) at 10-year follow-up suggest that beyond the effect of antipsychotic medication on weight changes, there are other clinical and social factors contributing to the weight gain in psychosis patients. This is consistent with previous articles showing that cardio-metabolic risk factors and abnormalities are present in early psychosis regardless of antipsychotic exposure (Jensen et al., 2017; Pillinger et al., 2017), thus suggesting that the cardio-metabolic alterations may be in part explained by the underlying illness itself. Other known clinical, social, and personal risk factors, such as unhealthy diet, low physical activity, and substance abuse, are known to contribute to the higher incidence of metabolic alterations in this population (Vancampfort et al., 2017; Firth et al., 2018).

### Strengths and Limitations

The main strength of this study is its design, a prospective longitudinal study with an uncommon long-term follow-up (10 years) on a cohort of well-characterized, drug-naïve FEP patients, and its comparison with a prospective sample of healthy individuals. Studying a cohort of drug-naïve patients with a FEP from the early stage of their psychotic disorder facilitates avoiding lack of statistical significance in the results might be explained by the fact that the mean duration of treatment discontinuation prior to the study was 0.67 years, probably not long enough to reverse the previous long-term metabolic effect of antipsychotic treatment.

Mackin and colleagues (Mackin et al., 2012) reported that discontinuing antipsychotic medication after several years of exposure was not associated with a complete reversal of the metabolic disturbances presented in the patients, suggesting that the consolidated metabolic dysregulation associated with the antipsychotic treatment is maintained long term (Mackin et al., 2012). Our results are in line with this study; FEP patients who had discontinued antipsychotic treatment in our sample presented lower changes in the lipid and glycemic parameters than those patients who continued on antipsychotic treatment, but greater changes than healthy non-psychiatric participants did. However, only statistically significant differences between the treated patients and control group were observed, suggesting that antipsychotic discontinuation was not associated with complete reversal of weight and metabolic changes.

### Table 1. Differences in Longitudinal Changes (“10-Year” Minus “Baseline” Measures) in Anthropometric and Metabolic Measurements Between Psychosis Patients Regarding Antipsychotic Treatment Status at 10-Year Follow-up

| Measurements                      | Patients on antipsychotic treatment | Patients who discontinued treatment | Controls | Stats\(^a\) | P\(^b\) |
|-----------------------------------|-------------------------------------|-------------------------------------|----------|-------------|--------|
| Mean diff (SD)                    | Mean diff (SD)                      | Mean diff (SD)                      |          |             |        |
| A: n = 175                        | B: n = 34                           | C: n = 57                           |          |             |        |
| Anthropometric measures           |                                    |                                     |          |             |        |
| Weight, kg                        | 16.53 (13.06)                       | 8.22 (6.80)                        | 2.89 (7.34) | 248         | 31.11  | <.001  | <.001 | .147  | <.001 |
| BMI, kg/m²                        | 5.88 (4.69)                         | 2.90 (2.45)                        | 1.03 (2.74) | 248         | 30.31  | <.001  | <.001 | .187  | <.001 |
| Waist circumference, cm           | 14.56 (12.19)                       | 7.12 (3.98)                        | 4.68 (7.14) | 79          | 11.82  | <.001  | .046  | 1.000 | <.001 |
| Lipid parameters                  |                                    |                                     |          |             |        |
| Cholesterol, mg/dL                | 21.33 (34.54)                       | 23.33 (30.97)                      | 8.79 (36.52) | 2; 210      | .723   | .468   | 1.000 | 1.000 | .693  |
| HDL, mg/dL                        | −2.10 (12.38)                       | 1.44 (12.93)                       | 2.75 (6.86) | 182         | 5.341  | .006   | .132  | 1.000 | .015  |
| LDL, mg/dL                        | 13.59 (28.49)                       | 14.96 (26.75)                      | 6.54 (31.44) | 2; 179      | 0.279  | .757   | .100  | 1.000 | 1.000  |
| Triglycerides, mg/dL              | 48.65 (76.24)                       | 22.04 (44.83)                      | −2.75 (52.79) | 2; 182      | 6.644  | .002   | .181  | .706  | .003  |
| Glycemic parameters               |                                    |                                     |          |             |        |
| Glucose, mg/dL                    | 4.74 (23.11)                        | 0.93 (10.89)                       | 4.42 (16.85) | 2; 209      | 2.926  | .056   | .772  | .961  | .073  |
| HOMA index                        | 1.13 (3.37)                         | 0.80 (1.81)                        | 0.16 (0.87) | 145         | 8.478  | <.001  | .184  | .510  | <.001  |
| HOMA index, men                    | 1.69 (2.88)                         | 0.57 (1.95)                        | −0.19 (0.92) | 2; 74       | 5.237  | .007   | .181  | 1.000 | .015  |
| HOMA index, women                  | 0.45 (3.80)                         | 0.99 (1.76)                        | 0.51 (0.67) | 66          | 4.022  | .022   | 1.000 | .252  | .018  |
| Triglycerides-HDL index            | 1.27 (2.14)                         | 0.33 (1.16)                        | −0.07 (0.97) | 2; 178      | 6.835  | .001   | .082  | 1.000 | .004  |
| Insulin, µU/mL                    | 3.71 (13.02)                        | 3.23 (6.81)                        | 0.19 (3.59) | 148         | 10.225 | <.001  | .108  | .474  | <.001  |
| Insulin, men                       | 5.64 (10.55)                        | 1.90 (7.10)                        | −0.78 (3.72) | 2; 75       | 6.692  | .002   | .107  | 1.000 | .005  |
| Insulin, women                     | 1.52 (15.16)                        | 4.43 (6.68)                        | 1.25 (3.27) | 68          | 4.469  | .015   | 1.000 | .262  | .012  |
| Hormonal levels                    |                                    |                                     |          |             |        |
| Leptin, ng/mL                      | 13.03 (13.39)                       | 9.40 (19.39)                       | 4.66 (4.52) | 143         | 5.709  | .004   | .691  | .382  | .003  |
| Leptin, men                        | 8.94 (10.81)                        | 1.42 (5.60)                        | 3.85 (4.64) | 72          | 4.270  | .018   | .093  | 1.000 | .081  |
| Leptin, women                      | 17.63 (14.58)                       | 16.65 (24.54)                      | 5.54 (4.40) | 66          | 4.384  | .016   | 1.000 | .063  | .016  |

Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein.

\(^a\)Statistics: ANCOVA model: parameter change was used as the dependent variable; participant group (patients on antipsychotic treatment vs discontinuers) was the fixed factor, and baseline BMI, baseline parameter data age, and sex were used as covariates.

\(^b\)Pairwise comparisons based on estimated marginal means; Bonferroni adjustment for multiple comparisons.
the confounding effect of chronicity and previous exposure to medications with a probable effect on metabolism.

On the other hand, the study presents several important limitations. Patients were not evaluated periodically for research purposes, thus leading to a widely spaced follow-up interval with a lack of clinical and social information in that long period. This may hinder controlling for other factors’ effect on weight and precludes proper analyses of weight trajectories. Another limitation of the study is that the data regarding treatment continuation or discontinuation are mainly based on patients and their families’ reports, which might explain the low rate of treatment discontinuation observed in this cohort (16%); the use of plasmatic levels of the antipsychotics prescribed would have provided more accurate information of treatment compliance.

Due to the long follow-up period, we were not able to account in the statistical analyses other factors known to contribute to weight changes such as diet and physical activity. Similarly, we were not able to carry out differential antipsychotic medication analysis mainly due to the long-term follow-up and the inability to control for other environmental and pharmacological confounding factors.

### Conclusions

Patients who discontinued antipsychotic treatment prior to the 10-year follow-up presented smaller weight gain and better metabolic progression long term than those who remained on antipsychotic treatment.

### Supplementary Materials

Supplementary data are available at International Journal of Neuropsychopharmacology (IJNPPY) online.

### Acknowledgments

The authors wish to thank all the PAFIP research team and all patients and family members who participated in the study.

| Table 2. Comparison of Proportion of Participants with Pathologic Parameters in Weight, Fasting Glucose, and Lipid Levels at Baseline and at 10-Year Follow-up in Each Patient Group |
|-------------------------------------------------|-----------------|----------------|-----------------|----------------|-----------------|
| BMI ≥30 kg/m²                                    | % (n)           | % (n)          | % difference   | n              | P*              |
| Discontinued group                               | 3.7 (1)         | 22.2 (6)       | 18.5           | 27             | <.001           |
| Antipsychotic group                              | 7.3 (11)        | 38.4 (58)      | 31.1           | 151            |               |
| Total                                           | 6.7 (12)        | 36.0 (64)      | 29.3           | 178            | <.001           |
| Glucose >110 mg/dL                               | 0 (0)           | 6.5 (2)        | 6.5            | 31             | —               |
| Discontinued group                               | 1.8 (3)         | 7.3 (12)       | 5.5            | 165            | .022            |
| Antipsychotic group                              | 1.5 (3)         | 7.1 (14)       | 5.6            | 196            | .007            |
| Insulin (µU/mL); men >15.7, women >17.3          | 0 (0)           | 10.5 (2)       | 10.5           | 19             | —               |
| Discontinued group                               | 10.7 (17)       | 34.8 (59)      | 24.1           | 112            | <.001           |
| Antipsychotic group                              | 9.2 (12)        | 31.3 (52)      | 22.1           | 131            | <.001           |
| HOMA; men >3.5, women >3.9                       | 0 (0)           | 10.5 (2)       | 10.5           | 19             | —               |
| Discontinued group                               | 8.2 (9)         | 33.6 (57)      | 25.4           | 110            | <.001           |
| Antipsychotic group                              | 7.0 (9)         | 30.2 (50)      | 23.2           | 129            | <.001           |
| Triglyceride/HDL index >3.5                      | 8.0 (2)         | 4.0 (1)        | 4.0            | 25             | 1.000           |
| Discontinued group                               | 11.5 (20)       | 27.3 (45)      | 15.8           | 139            | <.001           |
| Antipsychotic group                              | 11.0 (18)       | 23.8 (40)      | 12.8           | 164            | <.001           |
| Cholesterol >200 mg/dL                           | 19.4 (6)        | 38.7 (12)      | 19.3           | 31             | .070            |
| Discontinued group                               | 24.1 (40)       | 42.2 (70)      | 18.1           | 166            | <.001           |
| Antipsychotic group                              | 23.4 (46)       | 41.6 (82)      | 18.2           | 197            | <.001           |
| LDL cholesterol >130 mg/dL                       | 19.2 (5)        | 34.6 (9)       | 15.4           | 26             | .219            |
| Discontinued group                               | 25.2 (35)       | 35.3 (59)      | 10.1           | 139            | .024            |
| Antipsychotic group                              | 24.2 (40)       | 35.2 (58)      | 11.0           | 165            | .006            |
| HDL cholesterol <40 mg/dL                        | 23.1 (6)        | 15.4 (4)       | −7.7           | 26             | .625            |
| Discontinued group                               | 21.1 (30)       | 28.2 (40)      | 7.1            | 142            | .143            |
| Antipsychotic group                              | 21.4 (36)       | 26.2 (44)      | 4.8            | 168            | .280            |
| Triglycerides >150 mg/dL                         | 3.7 (1)         | 7.4 (2)        | 3.7            | 27             | 1.000           |
| Discontinued group                               | 7.8 (11)        | 27.7 (49)      | 19.9           | 141            | <.001           |
| Antipsychotic group                              | 7.1 (12)        | 24.4 (41)      | 17.3           | 168            | <.001           |

Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein.

a McNemar test for repeated measures.
This work was supported by the Instituto de Salud Carlos III (grant nos. PI020495, PI050427, and PI060507) and the Valdecilla Institute of Biomedical Research (grant no. NVAL17/24).

**Interest Statement**

J.V.-B., J.M.-v.S., M.G.-R., R.A.-A., M.J.-R., D.T.-G., and V.O.-G.d.F. report no conflicts of interest. M.B. has received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen B.C.-F. has received honoraria for his participation as a consultant and/or as a speaker at educational events from Adamed, Ferrer, Janssen-Cilag, Lundbeck, and Otsuka, and a research prize from Pfizer. B.C.-F. has received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen Johnson & Johnson, Lundbeck, and Otsuka Pharmaceuticals.

**References**

Ayesa-Arriola R, Ortiz-Garcia de la Foz V, Martinez-Garcia O, Setien-Suero E, Ramirez ML, Suarez-Pinilla P, Mayoral Van Son J, Vazquez-Bourgon J, Juncal-Ruiz M, Gomez-Revuelta M, Tordesillas-Gutierrez D, Crespo-Facorro B (2019) Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort. Psychol Med. Advance online publication. Retrieved 18 Nov 2019. doi:10.1007/S0032391719003179

Bioque M, Garcia-Portilla MAP, Garcia-Rizo C, Cabrera B, Lobo A, González-Pinto A, Díaz-Canaja CM, Corripio I, Vieta E, Castro-Fornieles J, Bobes J, Gutiérrez-Fraile M, Rodriguez-Jimenez R, Mezquida G, Llerena A, Saiz-Ruiz J, Bernardo M; PEPs GROUP (2018) Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. Schizophr Res 193:188–196.

First MB, Spitzer RL, Gibbon M, Williams JBW (1996) Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press, Inc.

Firth J, Stubbs B, Teasdale SR, Ward PB, Veronese N, Shivappa N, Hebert JR, Berk M, Yung AR, Sarris J (2018) Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. World Psychiatry 17:365–367.

Hui CLM, Honer WG, Lee EHM, Chang WC, Chan SKW, Chen ESM, Pang EPF, Lui SYY, Chung DWS, Yeung WS, Ng RMK, Lo WTL, Jones PB, Sham P, Chen EYH (2018) Long-term effects of discontinuation from antipsychotic maintenance following first episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry 5:432–442.

Hulvershom L, Parkhurst S, Jones S, Dauss K, Adams C (2017) Improved metabolic and psychiatric outcomes with discontinuation of atypical antipsychotics in youth hospitalized in a state psychiatric facility. J Child Adolesc Psychopharmacol 27:897–907.

Jensen KG, Correll CU, Rudå D, Klauber DG, Stentebjerg-Olesen M, Fagerlund B, Jepsen JRM, Fink-Jensen A, Pagsberg AK (2017) Pretreatment cardiometabolic status in youth with early-onset psychosis: baseline results from the TEA trial. J Clin Psychiatry 78:e1035–e1046.

Josiasen RC, Shaughnessy RA, Filymer DM, Donohue AM, Kacso M, Finkel N, Curtis J, Audino B, Skuban N (2010) Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study. Early Interv Psychiatry 4:57–63.

Lindenmayer JP, Liu-Seifert H, Kulkarni PM, Kinon BJ, Stauffer V, Edwards SE, Chen L, Adams DH, Ascher-Svanum H, Buckley FF, Citrome L, Volavka J (2009) Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. J Clin Psychiatry 70:990–996.

Mackin P, Waton T, Watkinson HM, Gallagher P (2012) A four-year naturalistic prospective study of cardiometabolic disease in antipsychotic-treated patients. Eur Psychiatry 27:50–55.

Malla A, Mustafa S, Rho A, Abadi S, Lepage M, Jober R (2016) Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: a one-year outcome study. Schizophr Res 174:120–125.

Mayoral-van Son J, de la Foz VO, Martinez-Garcia O, Moreno T, Pajariina-escobar M, Valdizan EM, Crespo-Facorro B (2016) Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry 77:492–500.

Melle I, Olay Johannesen J, Haahr UH, Ten Velden Hegelstad W, Joa I, Langeveld J, Larsen TK, Inger Opjordsmoen S, Qin P, Ivor Røssberg J, Rishovd Rund B, Simonsen E, Vaglum PJW, Mcclashan TH, Frist S (2017) Causes and predictors of premature death in first-episode schizophrenia spectrum disorders. World Psychiatry 16:217–218.

Parabighi A, Tettamanti M, D’Avanzo B, Barbato A; GiSAS study group (2016) Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. Acta Psychiatr Scand 133:63–75.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanche C, Martinez-Garcia O, Vazquez-Barquero JL (2007) A 12-week randomised clinical trial to evaluate metabolic changes in drug-naïve, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J Clin Psychiatry 68:1733–1740.

Perez-Iglesias R, Martinez-Garcia O, Pardo-Garcia G, Amado JA, Garcia-Unzueta MT, Tabares-Seisdedos R, Crespo-Facorro B (2014a) Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol 17:41–51.

Perez-Iglesias R, Ortiz-Garcia de la Foz V, Martinez Garcia O, Amado JA, Garcia-Unzueta MT, Agues-Arriola R, Suarez-Pinilla P, Tabares-Seisdedos R, Crespo-Facorro B (2014b) Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophr Res 159:90–94.

Pillinger T, Beck K, Gobjila C, Donocik JC, Jauhar S, Howes OD (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74:261–269.

Pillinger T, Beck K, Gobjila C, Donocik JC, Jauhar S, Howes OD (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74:261–269.

Pillinger T, Beck K, Gobjila C, Donocik JC, Jauhar S, Howes OD (2017) Impaired glucose homeostasis in first-episode schizophrenia: a systematic review and meta-analysis. JAMA Psychiatry 74:261–269.

Saloojee S, Burns JK, Motala AA (2016) Metabolic syndrome in South African patients with severe mental illness: prevalence and associated risk factors. Plos One 11:e0149209.

Stahl SM, Mignon L, Meyer JM (2009) Which comes first: atypical vs. typical antipsychotics? A review of the evidence. J Clin Psychiatry 70:990–996.

Stahl SM, Mignon L, Meyer JM (2009) Which comes first: atypical vs. typical antipsychotics? A review of the evidence. J Clin Psychiatry 70:990–996.

Stahl SM, Mignon L, Meyer JM (2009) Which comes first: atypical vs. typical antipsychotics? A review of the evidence. J Clin Psychiatry 70:990–996.

Stahl SM, Mignon L, Meyer JM (2009) Which comes first: atypical vs. typical antipsychotics? A review of the evidence. J Clin Psychiatry 70:990–996.
Vancampfort D, Firth J, Schuch FB, Rosenbaum S, Mugisha J, Hallgren M, Probst M, Ward PB, Gaughran F, De Hert M, Carvalho AF, Stubbs B (2017) Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. World Psychiatry 16:308–315.

Vázquez-Bourgon J, Pérez-Iglesias R, Ortiz-Garcia de la Foz V, Suárez Pinilla P, Díaz Martínez A, Crespo-Facorro B (2018) Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis. Psychopharmacology (Berl) 235:245–255.

Wu X, Huang Z, Han H, Zhong Z, Gan Z, Guo X, Diao F, Han Z, Zhao J (2014) The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia. Neuropsychiatr Dis Treat 10:1361–1368.